Glenmark Announces Appointment of Mr. Philip Andrew Gioia (Phil) as President North America and Global API Business
MUMBAI, India, December 2, 2013 /PRNewswire/ --
Glenmark Pharmaceuticals announces the appointment of Mr. Philip Andrew Gioia (Phil) as President North America and Global API business. Phil has taken charge of his responsibilities and will be based at Mahwah, NJ, USA. He will be reporting into the Chairman & Managing Director - Mr. Glenn Saldanha. In this role Phil will be responsible for the Generics and Branded business across North America as also the Global API Sales & Marketing. Phil has over 25 years of experience in the US pharmaceutical industry both in the generics and the branded space.
(Logo: http://photos.prnewswire.com/prnh/20130626/625083 )
On his appointment, Mr. Glenn Saldanha mentions, "We believe that with Phil's rich & diversified experience across the Generics & Branded Pharmaceutical businesses as well as Business Development, brings the necessary skills & acumen to lead and grow the North American operations and the API business of Glenmark."
Phil joins Glenmark from Bausch & Lomb (acquired by Valeant Pharmaceuticals, August 2013), where his career spanned nearly 5 years most recently as Global Head of Diversified Products and Business Development, Pharmaceuticals. He worked significantly on expanding Bausch & Lomb's product pipeline. Prior to that, he was Division Head - Pharmaceutical Business Unit, North America. His responsibilities included all aspects of P&L management in addition to overall strategic commercial operations for the brand, generic and OTC divisions.
Preceding Bausch & Lomb, Phil enjoyed 13 years of increased responsibility at Barr Pharmaceuticals, Inc. from 1995 until January 2009 (acquired by Teva Pharmaceuticals). He joined the generic business assuming increasing levels of responsibility, then built Barr's branded business as VP/SVP of Sales which included a 300+ person sales force focused on Women's Health. In 2007, Phil was appointed Senior Vice President (SVP) of the $1.6 billion US Generic Sales & Marketing business where he was involved in the portfolio planning, manufacturing, logistics and supply chain activities. He led the forecasting group, and was very involved in product selection, planning, and logistics; ensuring the best in class customer service with respect to supply and quality within the trade. Phil began his pharmaceutical career with Lederle Laboratories and Forest Pharmaceuticals in various sales and marketing positions.
About Glenmark
Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenues. (SCRIP 100 Rankings published in the year 2013). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid arthritis etc.] and Pain [neuropathic pain and inflammatory pain].
The company has a significant presence in branded generics markets across emerging economies including India. GPL along with its subsidiary has 14 manufacturing facilities in four countries and has six R&D centers. Its subsidiary, Glenmark Generics Limited services the requirements of the US and Western Europe generics markets. The API business sells its products in over 80 countries, including the US, various countries in the EU, South America and India.
Issued by: Glenmark Pharmaceuticals Limited
http://www.glenmarkpharma.com
SOURCE Glenmark Pharmaceuticals Ltd